



April 5, 2012

Shamoon Ahmad, MD
Southwest Cancer Clinic
3340 Topaz Street, Suite 100
Las Vegas, NV 89121

Re: Purchasing Medications from Foreign or Unlicensed Suppliers Could Result in Serious Harm to Patients; Another Counterfeit Found in U.S.

Dear Dr. Ahmad:

According to information received by the U.S. Food and Drug Administration (“FDA” or “Agency”), your medical practice purchased multiple medications from a foreign distributor named Richards Pharma, also known as Richards Services, Warwick Healthcare Solutions, or Ban Dune Marketing Inc. (BDMI). Many of the products sold and distributed by this distributor have not been approved by the FDA. The manufacture and handling of these products may not be of suitable quality to ensure safety or efficacy, and the products have not been proven to be safe and effective pursuant to FDA standards. The Agency is very concerned that products distributed by this distributor may cause harm to patients, because they may be unsafe or ineffective.

The Agency has learned that one of the products distributed by Richards Pharma is a counterfeit version of Roche’s Altuzan 400mg/16ml. Even if the version had not been counterfeit, Altuzan itself is *not* approved by FDA. Altuzan is the Turkish brand name for bevacizumab. Packaging or vials that claim to be Roche’s Altuzan with lot number B6021 found in the United States should be considered counterfeit. The counterfeit version of Altuzan does not contain any active ingredient.

Other drug products obtained from Richards Pharma, Richards Services, Warwick Healthcare Solutions, BDMI, or other foreign or unlicensed suppliers may be from unknown sources, may have unknown ingredients, may be counterfeit, or may not have been manufactured, transported or stored under proper conditions as required by U.S. law, regulations, and standards.

Purchasing prescription drug products, such as injectable cancer medications, from foreign or unlicensed suppliers puts patients at risk of exposure to drugs that may be fake, contaminated, improperly stored and transported, ineffective, and dangerous. In virtually all cases, purchasing unapproved prescription drugs from foreign sources violates the Federal Food, Drug, and Cosmetic Act and is illegal.

FDA requests that you cease using, and retain and secure *all* remaining products purchased from Richards Pharma, Richards Services, Warwick Healthcare Solutions, BDMI, or any other foreign or unlicensed U.S. sources until further notice. Please do not return any product(s) to the place

of purchase at this time. FDA is continuing to evaluate this situation, and we will provide further instructions regarding the disposition of the product(s) at a future date.

On January 13, 2012, FDA issued a notice to health care providers about the risks of purchasing unapproved injectable cancer medications from unlicensed sources.¹ This notice includes information on how to identify whether your distributor or the product you receive is legitimate.

Information regarding any criminal activity involving the importation and use of foreign unapproved drugs can be reported to FDA's Office of Criminal Investigations (OCI), www.fda.gov/oci.

Health care providers and patients are asked to report adverse events related to the use of suspect medications to the FDA's MedWatch Safety Information and Adverse Event Reporting Program either online, by regular mail, by fax, or by phone. Health care providers and patients can either:

- Complete and submit the report online: www.fda.gov/MedWatch/report.htm or
- [Download form](#) at: <http://www.fda.gov/downloads/Safety/MedWatch/HowToReport/DownloadForms/ucm082725.pdf>, or
- Call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

FDA is committed to promoting and protecting the public health by ensuring that only safe, effective, and high-quality drugs are available to the American public. Please contact Leigh Verbois at DrugSupplyChainIntegrity@fda.hhs.gov if you have any questions regarding this letter.

Sincerely,

/s/

S. Leigh Verbois, Ph.D.
Acting Deputy Director
Division of Supply Chain Integrity
Office of Drug Security, Integrity, and Recalls
Office of Compliance
Center for Drug Evaluation and Research

¹ Notice of Risks of Purchasing Unapproved Injectable Cancer Medications
<http://www.fda.gov/downloads/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/UCM287717.pdf>

cc: Douglas C. Cooper, CMBI, Executive Director, Nevada State Board of Medical
Examiners
Humayun J. Chaudhry, DO, FACP, President, Federation of State Medical Boards